Short answer: As of November 11, 2026, no controlled trial of MOTS-c in people has published results. ClinicalTrials.gov lists one placebo-controlled phase 2a trial of injected MOTS-c (NCT07505745): 120 adults with prediabetes and overweight or obesity, 12 weeks, started February 2, 2026, with results not expected before its estimated primary completion date of February 14, 2027. A phase 1 trial of a related compound, CB4211, finished in April 2021 but has no posted or published results we could find. MOTS-c is a research peptide: this page reports what is known and gives no dosing.
MOTS-c is sold widely online and is now one of six peptides in an October 2026 HHS compounding policy. That makes one question matter: what has actually been tested in people? We checked ClinicalTrials.gov, PubMed, FDA's July 2026 review and HHS's October 2026 appendix on November 11, 2026.
What MOTS-c is
MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA. It was described in a 2015 Cell Metabolism paper by Lee and colleagues, who reported that MOTS-c treatment in mice prevented diet-induced obesity and insulin resistance. The body makes it naturally, and many later studies measure people's own blood levels of it. Those studies tell us about natural MOTS-c, not about what happens when someone injects it.
Registered human trials
| Trial | What it tests | Status |
|---|---|---|
| NCT07505745 (MOTS-MET), sponsor Hudson Biotech, one site in Shenzhen, China | Phase 2a. Daily injections of MOTS-c or placebo under the skin for 12 weeks in 120 adults with prediabetes and overweight or obesity, plus lifestyle counseling. Main outcomes: insulin sensitivity (Matsuda index from a glucose tolerance test) and side effects through week 16. | Recruiting. Started February 2, 2026; first posted April 1, 2026; estimated primary completion February 14, 2027. |
| NCT03998514, sponsor CohBar, Inc. | Phase 1a/1b. CB4211, which a 2022 review in the Journal of Clinical Investigation describes as a MOTS-c analog, versus placebo under the skin in 88 healthy adults and adults with fatty liver disease. Tests safety, tolerability and blood levels. | Completed April 19, 2021. No results posted on ClinicalTrials.gov, and no matching paper on PubMed. |
CB4211 is not the same molecule as the MOTS-c sold online, so even published CB4211 results would not answer questions about MOTS-c itself.
What FDA said in July 2026
FDA reviewed MOTS-c for its Pharmacy Compounding Advisory Committee. Its briefing document found:
- No acute toxicity, repeat-dose toxicity or genotoxicity studies were submitted or found.
- FDA "did not identify clinical studies" for any of the nominated uses, which included insulin resistance, obesity, osteoporosis and longevity.
- FDA was "particularly concerned about the lack of human data" by any route, and said the immune-reaction risk of the 16-amino-acid peptide could not be assessed.
- MOTS-c acetate was not well characterized as a raw ingredient, in part because of inconsistent naming and missing test data.
FDA staff concluded that the balance of criteria "weighs against" adding MOTS-c, in either form, to the 503A bulks list.
What HHS said in October 2026
HHS's Appendix B to its draft policy covers MOTS-c acetate for injection under the skin or into muscle. It says newer certificates of analysis from FDA-registered makers fill FDA's testing gaps, that most documented use is single-ingredient, and that "a randomized placebo-controlled trial of a MOTS-c analogue reported no serious adverse events." HHS does not name the trial or cite a publication. The only registered placebo-controlled trial of a MOTS-c analogue we found is the CB4211 study above, and its results are not posted on ClinicalTrials.gov or published on PubMed.
What we still do not know
- Whether injected MOTS-c changes blood sugar, weight or anything else in people. The phase 2a trial is the first registered test of that.
- How it behaves in people after an injection. FDA wrote that it "remains to be determined" whether giving MOTS-c to humans produces active levels over time.
- Its immune-reaction risk and long-term side effects.
FDA also notes MOTS-c is listed as prohibited in the Global DRO sport drug database, which matters for tested athletes.
What this means for you
The honest summary is "promising in mice, untested in people so far." If you are considering MOTS-c, talk to your clinician first, and treat anything you read about doses as research information, not a plan. The phase 2a results, expected some time after February 2027, will be the first real human efficacy data. Our MOTS-c compound page tracks the research status.
Frequently asked questions
Has MOTS-c been tested in humans?+
When will MOTS-c trial results come out?+
What is CB4211?+
What did the FDA say about MOTS-c in 2026?+
Is MOTS-c in the HHS compounding policy?+
Related reading
- MOTS-c compound page
- HHS six-peptide compounding policy (2026)
- The FDA's 2026 peptide compounding decisions
- SS-31 (elamipretide), another mitochondria-targeted peptide
- NAD+ injections: what the evidence shows
- What "research use only" means
- How to track a peptide stack
- Compound library
Questions about the app? See the help center or join the Dose Track community.
Sources
Every fact in this article comes from one of these sources, checked on November 11, 2026. MOTS-c is a research peptide. This article is for education. It is not medical advice, and nothing here is a dose recommendation.
- ClinicalTrials.gov. NCT07505745: MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity (MOTS-MET). Record last updated April 1, 2026. clinicaltrials.gov
- ClinicalTrials.gov. NCT03998514: A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease. clinicaltrials.gov
- U.S. Food and Drug Administration. FDA Briefing Document, MOTS-c-related bulk drug substances (MOTS-c free base and MOTS-c acetate), Pharmacy Compounding Advisory Committee, July 23-24, 2026. fda.gov/media/193347/download
- U.S. Department of Health and Human Services. Appendix B: Peptide Identities and Justifications, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (October 2026). hhs.gov
- Federal Register. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, FR Doc. 2026-22192, October 30, 2026. federalregister.gov
- Miller B, et al. Mitochondria-derived peptides in aging and healthspan. J Clin Invest. 2022. PMID 35499074 (names CB4211 as a MOTS-c analog). PubMed
- Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015. PMID 25738459. PubMed